Y Intercept Hong Kong Ltd Purchases New Shares in Septerna, Inc. $SEPN

Y Intercept Hong Kong Ltd purchased a new position in Septerna, Inc. (NASDAQ:SEPN) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 25,770 shares of the company’s stock, valued at approximately $619,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SEPN. Group One Trading LLC increased its stake in shares of Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after purchasing an additional 8,955 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in Septerna in the 4th quarter worth about $35,000. Russell Investments Group Ltd. purchased a new stake in Septerna during the 3rd quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Septerna during the fourth quarter valued at approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Septerna during the fourth quarter valued at approximately $61,000.

Septerna Trading Down 4.4%

Septerna stock opened at $34.36 on Tuesday. The company has a 50-day moving average price of $31.41 and a 200 day moving average price of $27.98. Septerna, Inc. has a 12-month low of $10.62 and a 12-month high of $38.04. The stock has a market cap of $1.55 billion, a P/E ratio of -42.42 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, May 11th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The company had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. As a group, analysts forecast that Septerna, Inc. will post -1.59 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Guggenheim lowered their price target on Septerna from $52.00 to $45.00 and set a “buy” rating on the stock in a research note on Wednesday, July 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a report on Tuesday, April 21st. Stifel Nicolaus began coverage on shares of Septerna in a research note on Friday, May 1st. They set a “buy” rating and a $43.00 target price on the stock. Truist Financial increased their target price on shares of Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Finally, JPMorgan Chase & Co. upped their price objective on shares of Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $45.89.

Insider Activity at Septerna

In other Septerna news, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total transaction of $97,360.00. Following the completion of the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at $4,240,247.06. This trade represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Daniel D. Long sold 15,000 shares of Septerna stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $35.51, for a total value of $532,650.00. Following the completion of the sale, the senior vice president owned 96,412 shares in the company, valued at $3,423,590.12. This represents a 13.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 48,494 shares of company stock worth $1,566,751. Insiders own 5.80% of the company’s stock.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.